Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Pfizer CEO Ian Read's Turnaround Efforts Reap 44% Surge In 2011 Compensation

RELATED NEWS
Trade PFE now with 

Pharmaceutical giant Pfizer, Inc. (PFE: Quote) revealed in a proxy filing on Thursday that total fiscal 2011 compensation for its Chairman and Chief Executive Officer Ian Read surged 44 percent due to his turnaround efforts, reflecting strong increase in salary, annual cash incentive and stock grants.

According to the New York-based world's largest drugmaker, "2011 was a year marked by ongoing change throughout Pfizer brought about by a difficult market environment, increased pricing pressures and the loss of exclusivity of Lipitor."

However, under the leadership of Read, the company has undergone a restructuring to set a course to redefine and strengthen Pfizer to refocus as an innovative biopharmaceutical company.

Read oversaw the steady progress in Pfizer's late stage pipeline with over five approvals in the U.S. and E.U., and the advancement of about 30 programs in early- and mid-stage (Phase I and II) pipeline. The company also continued to invest in its R&D network and in the capabilities designed to drive biomedical innovation.

Effective January 2011, Read's base salary was set at $1.7 million, annual incentive target at $2.6 million, and long-term target was at $10.0 million.

The company added that Read does not receive any compensation for his service as a director or as chairman. Read served as president and CEO from December 2010, after the surprise resignation of Jeff Kindler, until his election as chairman and CEO in December 2011.

For fiscal 2012, the company's compensation committee has in February increased Read' base salary marginally to $1.75 million, and advanced his annual cash incentive target to 150 percent of base salary.

The company noted that Read's total compensation for fiscal 2011 was $25 million, up 44 percent from the $17.4 million he received in fiscal 2010.

Read's fiscal 2011 compensation included salary of $1.7 million, stock awards of $5.68 million, option awards of $6.92 million, annual incentive of $3.5 million, deferred compensation of $6.89 million, and all other compensation of $0.32 million.

Meanwhile, his fiscal 2010 compensation included salary of $1.2 million, stock awards of $2.67 million, option awards of $0.84 million, annual incentive of $1.5 million, deferred compensation of $10.98 million, and all other compensation of $0.21 million.

PFE closed Thursday's regular trading session at $21.91, down $0.02 or 0.09% on a volume of 30.91 million shares.

Register
To receive FREE breaking news email alerts for Pfizer Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After ending the previous session modestly lower, stocks are turning in a lackluster performance in early trading on Thursday. The major averages have turned mixed on the day, with the Dow benefiting from a strong gain by shares of Visa (V). Hundreds of protesters stormed Burkina Faso's parliament on Thursday and set fire to the building, preventing the lawmakers from considering a bill to extend the president's 27-year rule. Security forces opened fire on protesters, as they looted computers and televisions in the National Assembly, news agencies reported. The angry crowd then marched towards the President's office, before they were U.S. economic activity increased by more than expected in the third quarter of 2014, according to a report released by the Commerce Department on Thursday. The Commerce Department said GDP increased by 3.5 percent in the third quarter compared to 3.0 percent growth expected by economists.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.